Main Article Content

Authors

Calcium charmel blockers have a central role in treating certain cardiovascular disorders; their integrating families modify the dynamic of the cardiovascular system in different ways, which is critical in the election of the drug according to the specific clinical situation. A greater knowledge of the interaction between these drugs and calcium channels offers better comprehension of existing differences. The present paper, by reviewing biochemical and electrophysiological discrepancies in this interaction, propounds an explanation for the drug's effects on the cardiovascular system.

Naydú Arana, Profesora Auxiliar, Departamento de Farmacología, E1CUela de Cienciu B6sicas, Facuhad de Salud, Univenidad del Valle, Cali, ColombiL 

Profesora Auxiliar, Departamento de Farmacología, E1CUela de Cienciu B6sicas, Facuhad de Salud, Univenidad del Valle, Cali, ColombiL 

Mariela Pantoja, 2. Profesora Asociada

2. Profesora Asociada, Departamento de Farmacología, Escuela de Ciencias Básicas, Facultad de Salud, Universidad del Valle, Cali, ColombiaL

Juan F Maya, Profesor Asistente, Departamento de Farmacología, Escuela de Ciencias básicas, Facultad de Salud, Universidad del Valle, Cali, Colombia

Profesor Asistente, Departamento de Farmacología, Escuela de Ciencias básicas, Facultad de Salud, Universidad del Valle, Cali, Colombia

Messerli,F,Oren,S&Grossman,E. Effects of calcium channel blockers on systemic hemodynamics in hypertension. AmJ M ed, 1988, 84 (suppl 3B): 8-12. DOI: https://doi.org/10.1016/0002-9343(88)90181-7

Hondcghem,. LM. & Katzung, N. Antiarrhythmic agents: thc modulated receptor mechanism of action of sodium and calcium channel-blocking drugs. Ann RevPharmacolToxicol, 1984,4:387-243. DOI: https://doi.org/10.1146/annurev.pa.24.040184.002131

Aeckenstein, A. Calcium antagonism in heart and smooth muse/e. Experimental facts and therapeutic prospects. John Wiley & Sons, New York, 1983.

Henry, PD. Comparative pharmacology of calcium antagonists: nifedipine, verapamil, and diltiazem. Am J Cardiol, 1980, 46: 1047-1058. DOI: https://doi.org/10.1016/0002-9149(80)90366-5

Fleckcnstein, A. History of calcium antagonists.CircRe.f, 1983,52 (suppl. I): 3-16.

Porzig, H. Pharmacological modulation of voltage-dependent calcium channels in intact cells. Rev Physiol Biochem Pharmacol, 1990, 114:200-262.

Pelzer, D., Pelzer, S. & McDonald, T. Properties and regulation of calcium channels in muscle calls. Rev Physiol BiochemPharmacol, 1990, ll4: 108-207. DOI: https://doi.org/10.1007/BFb0031019

Glossmann, H. & Striessning,J. Molecular properties of calcium channels. Rev Physiol Biochem Pharmacol, 1990, / /4:1-10.5.

Spedding, M. & Paolletti, R. Classification of calcium channels and the sites of action of drugs modifying channel function. Pharmacol Rev 1992, 44: 363-376.

Hcss, P. Calcium channels in vertebrate cclls. Ann Rev Newo.Jci,1.990, 13: 337-356. DOI: https://doi.org/10.1146/annurev.ne.13.030190.002005

Lanzdunski, M. Calcio, canales de calcio y bloqueadores de canales de calcio. Cardiovasc RevRep, 1992, 4: 212-219.

Sperclakis, N. Función del sarcolema en el acoplamiento excitación-contracción del músculo cardíaco. Cardiovasc Rev Rep, 1992, 9: 418-425.

Tsien, RW, Ellinor, PT. & Home, W A. Molecular diversity of voltage-dependent Ca2•channels. TrendsPharmaco/Sci, 1991, 12: 349-354. DOI: https://doi.org/10.1016/0165-6147(91)90595-J

Schwartz, A. Molecular and ce U u lar aspects of calcium channel antagonism. Am J Cardiol, 1992, 70: 6f-8f. DOI: https://doi.org/10.1016/0002-9149(92)90182-X

Catterall, WA & Striessnig, J. Receptor sites for ea•• channel antagonists. Trend.f Pharmacol Sci, 1992, 13: 256-262. DOI: https://doi.org/10.1016/0165-6147(92)90079-L

Catterall, W.A. Functionalsubunitstruclllre of voltage-gated calcium channels. Science, 1991, 253: 1499-1500. DOI: https://doi.org/10.1126/science.1654596

Tanabe, T, Takeshima, H, Mikami, A, et al. Primary structure of the receptor for calcium channel blockers from skeletal muscle. NaJwe, 1981,328: 313-318, DOI: https://doi.org/10.1038/328313a0

Takahashi, M, Seagar, MJ, Jones, JF, Reber, BF. & Catterall, W A. Subunit structure of dihydropyridine sensitive calcium channels from skeletal muscle. Proc Natl Acad Sci, 1981, 84: 5478-5482. DOI: https://doi.org/10.1073/pnas.84.15.5478

Singer, D, Bici, M. Lotan, l. Aockerzi, V. Hofmann, F. & Dascal, N The roles of the subunits in the function of calcium channel. Science, 1991, 253: 1553-1557. DOI: https://doi.org/10.1126/science.1716787

Yarady, G, Lory, P. & Schultz, D . Acceleration of activation and inactivation by the b subunit of the skeletal muscle calcium channel. Natwe, 1991, 352: 159-162. DOI: https://doi.org/10.1038/352159a0

Katz, AM. Cardiac ion channels. N Engl J Med, 1993, 328: 1244-1251. DOI: https://doi.org/10.1056/NEJM199304293281707

Olivari, M, Bartorelli, C. Polose, A. Fiorentini, C. Moruzzi, P. & Guazzi, M. Treatmentofhypertension with nifedipine, a calcium antagonist agent. Circula/ion, 1979, 59: 1056-1062. DOI: https://doi.org/10.1161/01.CIR.59.5.1056

Mitchell, LB, Schroeder, JS. & Mason, JW. Comparative clinical electrophysiologic effects of diltiazem, verapamil and nifedipine: a review. Am J Cardiol, 1982, 49: 629-635. DOI: https://doi.org/10.1016/S0002-9149(82)80022-2

Low, R, Takeda, P, Mason, D. & DeMaria, A. The effects of calcium channel blocking agents on cardiovascular function. Am J Cardiol, 1982, 49: 547-553. DOI: https://doi.org/10.1016/S0002-9149(82)80010-6

Hansson, L. Calcium antagonists: an overview.AmfleartJ, 1991, 122: 308-411. DOI: https://doi.org/10.1016/0002-8703(91)90839-A

Frohlich, E. Calcium antagonists as cardioprotectiveagents.AmJ Cardiol, 1992, 70: 71-91. DOI: https://doi.org/10.1016/0002-9149(92)90259-2

Piepho, RW & Sower, JR. Antihypertensive therapy in the geriatric patient: a review of the role of calcium channel blockers. J Clin Pharmacol, 1992, 29: 193-200. DOI: https://doi.org/10.1002/j.1552-4604.1989.tb03312.x

Mitchell, J, Frishman, W & Elliman, M. Nisoldipine: a new dihydropyridine calcium channel blocker. J Clin Pharmacol, 1993, 33: 46-52. DOI: https://doi.org/10.1002/j.1552-4604.1993.tb03902.x

Guazzi, M. Olivari, M, Polcse, A, Magrini, T.R. & Moruzzi, P. Nifedipine, a new antihypertensive with rapid action. Clin Pharmaco/Ther, 1977, 22: 528-532. DOI: https://doi.org/10.1002/cpt1977225part1528

Ludbrook, P.A., Tiefenbrunn, AJ, Reed, FR, & Sobe), BE. Acute hemodynamic responses to sublingual nifedipine: dependence on left ventricular function. Circulation, 1982, 65: 489-498.

Ram, CV. Nicardipine for systemic hypertension: effects on blood pressure and target organ function. Am J Cardiol, 1987, 59: 25j-30j.

Feldman, RL, Pcpine, U & Whitlc,J. Short and long-term responses to diltiazem in patients with variant angina.AmJ Cardiol, 1982, 49: 555-559.

Bassan, M, Weiler, D. & Shalev, O. The additive antianginal action of oral nifedipine in patients receiving propranolol. Magnitude and duration of effect. Circulation, 1982, 66: 710-716.

Johnston D, Lesoway, R, Humen, DP, & Kostuk, WJ. Clinical and hemodynamical evaluation of propranolol in combination with verapamil, nifedipine and diltiazem in exertional angina pectoris. A placebo-controlled, double-blind, randomized, crossover study. Am J Cardiol, 1984, 55: 680-687.

Danilo, P, Hordof AJ, Reder, RF, & Rosen, M. Effects of verapamil on electrophysiologic properties of blood superfused cardiac Purkinje fibers Pharmacol Exp Therap, 1980, 213: 222-227.

Ludbrook, P.A., Tiefenbrunn, AJ, Reed, FR, & Sobe), BE. Acute hemodynamic responses to sublingual nifedipine: dependence on left ventricular function. Circulation, 1982, 65: 489-498. DOI: https://doi.org/10.1161/01.CIR.65.3.489

Ram, CV. Nicardipine for systemic hypertension: effects on blood pressure and target organ function. Am J Cardiol, 1987, 59: 25j-30j. DOI: https://doi.org/10.1016/0002-9149(87)90210-4

Feldman, RL, Pepine, U & Whitle, J. Short and long-term responses to diltiazem in patients with variant angina.AmJ Cardiol, 1982, 49: 555-559. DOI: https://doi.org/10.1016/S0002-9149(82)80011-8

Bassan, M, Weiler, D. & Shalev, O. The additive antianginal action of oral nifedipine in patients receiving propranolol. Magnitude and duration of effect. Circulation, 1982, 66: 710-716. DOI: https://doi.org/10.1161/01.CIR.66.4.710

Johnston D, Lesoway, R, Humen, DP, & Kostuk, WJ. Clinical and hemodynamical evaluation of propranolol in combination with verapamil, nifedipine and diltiazem in exertional angina pectoris. A placebo-controlled, double-blind, randomized, crossover study. Am J Cardiol, 1984, 55: 680-687. DOI: https://doi.org/10.1016/0002-9149(85)90136-5

Danilo, P, Hordof AJ, Reder, RF, & Rosen, M. Effects of verapamil on electrophysiologic properties of blood superfused cardiac Purkinje fibers Pharmacol Exp Therap, 1980, 213: 222-227.

Soler,J, Sauleda, S. &Cabrera.A. Effcctof Soler,J, Sauleda, S. &Cabrera.A. Effcctof vcrapamil in infants with paroxysmal supravcntricular tachycardia. Circulation, 1919, 59: 876-879. Heschclcr, J, Pclzcr, D. Trubc, G. & DOI: https://doi.org/10.1161/01.CIR.59.5.876

Heschclcr, J, Pclzcr, D. Trubc, G. & Trautwein, W. Docs thc organic calcium channel blocker D600 act from inside or outside on the cardiac cell membrane? Pjlügers Arch Eur J Physiol, 1982, 393: 287-291. DOI: https://doi.org/10.1007/BF00581411

Kass, RS, Arcna, JP, & Chin, S. íllockofL-type calcium channels by charged dihydropyridines. Sensitivity to side of application and calcium. (Abstr) J Gen Physiol, 1991, 98: 63-75. DOI: https://doi.org/10.1085/jgp.98.1.63

Bcan, BP. Nitrcndipinc block of cardiac calcium channels: high affinity binding to the inactivated state. Proc Natl Acad Sci 1984, 8/: 6388-6392. DOI: https://doi.org/10.1073/pnas.81.20.6388

Arana, N., Pantoja, M., & Maya, J. F. (1994). Calcium antagonists and cardiovascular system. Pharmacodynamic differences. Colombia Medica, 25(3), 115–119. https://doi.org/10.25100/cm.v25i3.6520

Downloads

Download data is not yet available.